Display options
Cite
Sharif MR, Soltani B, Moravveji A, et al. Prevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran). Electron Physician. 2016;8(3):2081-7doi: 10.19082/2081.
Sharif, M. R., Soltani, B., Moravveji, A., Erami, M., & Soltani, N. (2016). Prevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran). Electronic physician, 8(3), 2081-7. https://doi.org/10.19082/2081
Sharif, Mohammad Reza, et al. "Prevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran)." Electronic physician vol. 8,3 (2016): 2081-7. doi: https://doi.org/10.19082/2081
Sharif MR, Soltani B, Moravveji A, Erami M, Soltani N. Prevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran). Electron Physician. 2016 Mar 25;8(3):2081-7. doi: 10.19082/2081. eCollection 2016 Mar. PMID: 27123215; PMCID: PMC4844472.
Copy Download .nbib Format: NLM
Share it on

Electron Physician. 2016 Mar 25;8(3):2081-7. doi: 10.19082/2081. eCollection 2016 Mar.

Prevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran).

Electronic physician

Mohammad Reza Sharif, Babak Soltani, Alireza Moravveji, Mahzad Erami, Nika Soltani

Affiliations

  1. Department of Pediatrics, Kashan University of Medical Sciences, Kashan, Iran.
  2. Department of Community Medicine, Trauma Research Center, Kashan University of Medical Sciences, Kashan, Iran.
  3. Department of Microbiology, Kashan University of Medical Sciences, Kashan, Iran.
  4. Student Research Committee, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 27123215 PMCID: PMC4844472 DOI: 10.19082/2081

Abstract

INTRODUCTION: Production of extended spectrum beta lactamase (ESBL) is an important mechanism of antimicrobial resistance in Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) isolates. This study was performed to determine the prevalence and risk factors associated with ESBL producing strains of E. coli and K. pneumoniae.

METHODS: In this cross-sectional study, 250 strains (134 E. coli and 116 K. pneumoniae) were obtained, and ESBL producing isolates were detected by the combination disk test in Shahid Beheshti Hospital in Kashan, Iran, from February 2012 to June 2013. Antimicrobial resistance was screened by the disk diffusion method and was confirmed by E-test. Furthermore, risk factors of ESBL producing E. coli and K. pneumoniae microorganisms were determined. Data were analyzed by SPSS version 16, using descriptive statistics, chi-squared, independent-samples t-test, and logistic regression analysis.

RESULTS: One hundred and two (40.8%) of all strains were ESBL producers, of which 54 (52.9%) were E. coli and 48 (47.1%) were K. pneumoniae (p = 0.86). Furthermore, 40.3% of E. coli and 41.4% of K. pneumoniae isolates were ESBL producers (p = 0.86). The most antimicrobial resistance was to ampicillin, and no imipenem resistance was detected. Risk factors for ESBL producing E. coli included admission duration exceeding 7 days (p = 0.011) and antibiotic use in the last month (p < 0.001), and the associated risk factor for ESBL producing K. pneumoniae was antibiotic use during the recent month (p = 0.002).

CONCLUSION: This study identified a relatively high prevalence of ESBL production among E. coli and K. pneumoniae strains. Furthermore, anti-bimicrobial use and admission duration were risk factors for ESBL producing isolates. Therefore, more comprehensive investigations are needed for the development of new strategies to control the dissemination of these microbes.

Keywords: ESBL; Escherichia coli; Klebsiella pneumoniae; risk factors

References

  1. Expert Opin Pharmacother. 2008 Jan;9(1):23-37 - PubMed
  2. BMC Res Notes. 2013 Jul 27;6:298 - PubMed
  3. Acta Microbiol Immunol Hung. 2009 Mar;56(1):89-99 - PubMed
  4. Clin Microbiol Rev. 2005 Oct;18(4):657-86 - PubMed
  5. J Infect Dev Ctries. 2009 May 01;3(4):295-9 - PubMed
  6. Antimicrob Agents Chemother. 2008 Aug;52(8):2818-24 - PubMed
  7. J Trop Pediatr. 2010 Apr;56(2):90-6 - PubMed
  8. Am J Med. 2006 Jun;119(6 Suppl 1):S20-8; discussion S62-70 - PubMed
  9. Trends Mol Med. 2012 May;18(5):263-72 - PubMed
  10. J Chemother. 2008 Aug;20(4):445-51 - PubMed
  11. Yonsei Med J. 2008 Feb 29;49(1):53-7 - PubMed
  12. J Infect Dev Ctries. 2010 Mar 29;4(3):132-8 - PubMed
  13. Iran J Kidney Dis. 2008 Oct;2(4):197-200 - PubMed
  14. Front Microbiol. 2015 Jun 16;6:595 - PubMed
  15. Clin Microbiol Rev. 2001 Oct;14(4):933-51, table of contents - PubMed
  16. Lancet Infect Dis. 2008 Mar;8(3):159-66 - PubMed
  17. Med Princ Pract. 2008;17(1):32-6 - PubMed
  18. BMC Pharmacol Toxicol. 2015 Jun 02;16:14 - PubMed
  19. Saudi J Biol Sci. 2015 Jan;22(1):37-41 - PubMed
  20. J Clin Diagn Res. 2013 Oct;7(10):2173-7 - PubMed

Publication Types